The End of an Era: Vivodyne Ignites Drug Discovery Revolution, Ditches Failing Animal Tests

- For decades, a staggering 95% of drugs acing animal tests have tragically failed in human trials5.
- Vivodyne is spearheading a revolution, replacing outdated animal models with thousands of AI-powered, lab-grown human organ tissues1, 7.
- With a fresh $40 million in funding, Vivodyne is scaling this breakthrough to deliver safer, more effective medicines, faster5.
The biopharmaceutical world has long grappled with a grim reality: countless cures celebrated in animal labs crumble when faced with human biology, a heartbreaking 95% failure rate that has stalled progress for decades5. But a new dawn is breaking. Vivodyne, founded by Dr. Andrei Georgescu and Dr. Dan Huh, is boldly rewriting the rules of drug discovery1, 7. They're not just tweaking the old system; they're building a new one from the ground up, powered by robotics, artificial intelligence, and lab-grown, fully functional human tissues that mirror our own complex biology1, 3, 5.
"A model that is only predictive 5% of the time isn’t a model," declares Dr. Georgescu, Vivodyne’s CEO. "We’re redefining success."5
Fueled by a $40 million Series A investment led by Khosla Ventures, Vivodyne is launching a sprawling 23,000-square-foot robotic laboratory in South San Francisco5. This facility will dramatically expand their capacity to test therapies on over 20 distinct human tissue types—from bone marrow to liver and lung—replicating diseases like cancer and autoimmunity5. This isn't just about avoiding animal suffering; it's about getting life-saving drugs to patients by generating unprecedented, human-relevant data before costly clinical trials. As the FDA and NIH signal a move away from less predictive animal models, Vivodyne is leading the charge, offering pharma giants the human-specific insights they've desperately needed5, 8. The age of failed promises is ending; the era of human-first drug discovery has begun.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.